ROY S. WEINER, M.D.; MORTIMER M. BORTIN, M.D.; ROBERT PETER GALE, M.D., Ph.D.; ELIANE GLUCKMAN, M.D.; HUMPHREY E. M. KAY, F.R.C.Path.; HANS-JOCHEM KOLB, M.D.; ARTHUR J. HARTZ, M.D., Ph.D.; ALFRED A. RIMM, Ph.D.
Data from 932 patients with leukemia who received bone marrow transplants were analyzed to determine factors associated with an increased risk of developing interstitial pneumonitis. Interstitial pneumonitis developed in 268 patients for a 2-year actuarial incidence of 35 ± 4% (SD) and with a mortality rate of 24%. Six factors were associated with an increased risk: use of methotrexate rather than cyclosporine after transplantation (relative risk, 2. 3; p < 0.0002); older age (relative risk, 2.1; p < 0.0001); presence of severe graft-versus-host disease (relative risk, 1.9; p ;< 0.003); long interval from diagnosis to transplantation (relative risk, 1.6; p < 0.002); performance ratings before transplantation of less than 100% (relative risk, 2.1; p < 0.0001); and high dose-rates of irradiation in patients given methotrexate after transplantation (relative risk, 3.2; p < 0.03). The risk of developing interstitial pneumonitis ranged from 8% in patients with none of these adverse risk factors to 94% in patients with all six. These findings may help to identify patients at high risk for this complication.
WEINER RS, BORTIN MM, GALE RP, et al. Interstitial Pneumonitis After Bone Marrow Transplantation: Assessment of Risk Factors. Ann Intern Med. 1986;104:168–175. doi: 10.7326/0003-4819-104-2-168
Download citation file:
Published: Ann Intern Med. 1986;104(2):168-175.
Hematology/Oncology, Interstitial Lung Disease, Pulmonary/Critical Care.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use